Nurix Therapeutics (NRIX) FCF Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of FCF Margin data on file, last reported at 1082.09% in Q2 2026.

• On a quarterly basis, FCF Margin fell 94417.0% year-over-year to 1082.09% in Q2 2026; TTM through May 2026 was 807.23%, a 56287.0% decrease from a year earlier, with the FY2025 full-year figure at 298.46%, up 2093.0% from the prior year.
• FCF Margin for Q2 2026 stood at 1082.09%, up from 1177.46% in the prior quarter.
• Over the last five years, FCF Margin for NRIX reached as high as 210.26% in Q4 2023 and fell as low as 1177.46% in Q1 2026.
• Historically, FCF Margin has averaged 423.25% across 5 years, with a median of 363.29% in 2024.
• Across the five-year window, FCF Margin surged 80763 bps in 2023 and tumbled 94417 bps in 2026, its largest moves.
• Year by year, FCF Margin stood at 597.38% in 2022, then jumped by 135 bps to 210.26% in 2023, then tumbled by 255 bps to 325.4% in 2024, then tumbled by 51 bps to 492.71% in 2025, then plunged by 120 bps to 1082.09% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 1082.09% in Q2 2026, 1177.46% in Q1 2026, and 492.71% in Q4 2025.